Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $5.00 price target on the stock, down from their previous price target of $7.00. HC Wainwright's price target would suggest a potential upside of 195.86% from the stock's previous close.

Several other research analysts also recently issued reports on the stock. Stephens started coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They set an "overweight" rating and a $13.00 price objective on the stock. Royal Bank of Canada restated an "outperform" rating and set a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a research note on Friday. Finally, William Blair downgraded Pyxis Oncology from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Pyxis Oncology has an average rating of "Moderate Buy" and a consensus target price of $9.43.

Pyxis Oncology Price Performance

PYXS stock traded up $0.15 on Friday, reaching $1.69. 1,773,492 shares of the company were exchanged, compared to its average volume of 795,458. The firm has a market capitalization of $100.50 million, a PE ratio of -1.64 and a beta of 1.00. Pyxis Oncology has a 12 month low of $1.49 and a 12 month high of $6.85. The stock's fifty day moving average price is $2.93 and its 200 day moving average price is $3.30.

Insider Buying and Selling at Pyxis Oncology

In other news, CFO Pamela Ann Connealy bought 88,850 shares of Pyxis Oncology stock in a transaction dated Tuesday, November 26th. The shares were bought at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the purchase, the chief financial officer now owns 1,199,143 shares of the company's stock, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.80% of the company's stock.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. bought a new stake in Pyxis Oncology during the third quarter worth about $1,405,000. Bank of New York Mellon Corp grew its position in Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company's stock worth $1,031,000 after acquiring an additional 149,522 shares during the last quarter. abrdn plc increased its holdings in Pyxis Oncology by 28.9% during the 3rd quarter. abrdn plc now owns 913,045 shares of the company's stock valued at $3,351,000 after purchasing an additional 204,742 shares in the last quarter. Millennium Management LLC raised its position in Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock valued at $4,425,000 after purchasing an additional 743,499 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in Pyxis Oncology in the 2nd quarter valued at $3,462,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.